United States Patent 6,071,498: Scope, Claim Construction, Expiration, and Dry-Powder Inhaler Patent Landscape

U.S. Patent No. 6,071,498 covers a dry-powder inhaler with a mechanically activated visual indicator showing that a dose is ready for inhalation. The strongest protection is concentrated in the combination of a two-step operating sequence, a readiness display, and a dose-use or dose-remaining display. The patent is directed to inhaler hardware and user-interface mechanics, not to a particular active pharmaceutical ingredient.

The patent issued on June 6, 2000. Its ordinary 20-year patent term has expired, with the effective expiration falling in the 2017-2018 period depending on the controlling U.S. filing date and any applicable term adjustment. It therefore does not create current U.S. exclusivity or a present Paragraph IV barrier for a drug product. [1][2]

What technology does U.S. Patent 6,071,498 protect?

The patent protects a dry-powder inhaler that uses visual feedback to communicate two operating conditions:

The inhaler has been prepared for immediate dose discharge.
A dose has been discharged or removed from the inhaler.

The central concept is a mechanically activated display linked to the inhaler’s dose-metering mechanism. The display changes when the user depresses a metering button and changes again, or removes a symbol, after the patient inhales the dose.

The claims cover:

Powdered medicaments delivered through an air stream.
A metering button or similar preparation mechanism.
A two-step operating sequence.
A visual readiness indicator.
A removable or replaceable medicament cartridge.
A visual dose counter.
Viewing access from the mouthpiece side.
Display visibility while the device is held in the inhalation position.

The patent does not claim:

A specific drug.
A particular powder formulation.
A particular carrier such as lactose.
A particular capsule, blister, or reservoir geometry unless incorporated into the claimed cartridge structure.
A treatment method.
A manufacturing process for the medicament.

What are the independent claims in U.S. Patent 6,071,498?

Claims 1 and 9 are the independent claims. They define two different infringement routes.

Claim 1: Two-step operation plus mechanical readiness display

Claim 1 requires an inhaler with all of the following elements:

Claim element	Technical requirement
Inhaler type	Inhaler for powdered medicaments
Delivery mechanism	Medicament received by the patient through an air stream
Operating sequence	Two-step operation
First step	Depressing a metering button
Functional result	The inhaler enters a state of readiness
Second step	Subsequent inhalation of a dose
Display	Mechanically activated visual display
Display function	Indicates readiness for immediate discharge of the dose

The most important limitation is the relationship between the metering button, the ready state, and the visual display. A device that merely counts doses, without mechanically indicating that a dose has been prepared for immediate inhalation, would not literally satisfy the full claim.

Claim 1 also requires a two-step sequence. A passive inhaler that dispenses powder only through inhalation, without a separate button-operated preparation step, presents a substantial non-infringement position against this claim.

Claim 9: Dual visual displays

Claim 9 is broader in some respects because it does not expressly recite the metering-button sequence. It requires:

A dry-powder inhaler.
A first visual display indicating readiness for immediate discharge.
A second visual display indicating the number of doses removed from the inhaler.

Claim 9 is narrower in another respect because it requires two separate display functions. A single display that communicates both conditions could create claim-construction issues, but literal infringement would depend on whether the display constitutes both a first and second visual display under the ordinary meaning of the claim.

The independent claims can be compared as follows:

Issue	Claim 1	Claim 9
Powdered medicament	Required	Required
Air-stream delivery	Required	Required by the preamble
Metering button	Required	Not expressly required
Two-step operation	Required	Not expressly required
Ready indication	Required	Required
Mechanical activation	Expressly required	Not expressly required
Dose-use indication	Not required in the independent claim	Required
Replaceable cartridge	Not required	Not required
Side or inhalation-position viewing	Added by dependent claims	Added by dependent claims

How do claims 2 through 8 narrow the patent scope?

Claims 2 through 8 depend from claim 1 and add structural or ergonomic limitations.

Claims 2 and 4: Replaceable cartridge and cartridge display

Claim 2 requires a receptacle for receiving a replaceable cartridge. It does not, by itself, require that the cartridge contain a dose counter.

Claim 4 adds a cartridge visual display indicating either:

The number of doses used; or
The number of doses remaining.

The inhaler must also include a mechanism for reading that cartridge display from outside the inhaler.

This limitation is important for modular inhalers using replaceable medication cartridges. A device with an internal dose counter located entirely in the inhaler body may fall outside claim 4 if the cartridge itself does not carry the visual dose information.

Claims 3 and 10: Removable readiness symbol

Claims 3 and 10 require a readiness display containing a symbol that is removed after the medicament dose is discharged.

This is narrower than a display that merely changes color or increments a number. The claim language focuses on removal of a symbol. Examples could include:

A disappearing colored field.
A shutter that covers or uncovers a symbol.
A mechanically advanced indicator strip.
A window in which a ready mark is removed from view.

The legal question is whether the accused device removes the symbol itself or merely replaces it with another symbol. That distinction could affect literal infringement and equivalents analysis.

Claims 5 through 8: Viewing position and mouthpiece orientation

Claims 5 and 6 require the display or cartridge display to be viewable from the side of the inhaler where the mouthpiece is located.

Claims 7 and 8 require the display to be visible when the user positions the inhaler for inhalation.

These claims address user ergonomics rather than dose-metering chemistry. They protect the placement and orientation of the indicator. An inhaler with the same underlying dose mechanism but a counter visible only from the opposite side may avoid these dependent claims while remaining potentially relevant to claims 1 or 9.

How do claims 11 through 14 narrow claim 9?

Claims 11 through 14 add cartridge, numerical, and viewing limitations to claim 9.

Claim	Added limitation
11	Receptacle for a replaceable cartridge
12	Visual display includes a numerical display
13	First readiness display is visible from the mouthpiece side
14	Second display is visible in the user’s inhalation position

Claim 12 is particularly relevant to conventional dose counters. It requires a numerical display, not merely a color change, symbol, or mechanical flag. A red-green indicator may satisfy the broader display concept of claim 9 but would not necessarily satisfy claim 12.

What is the likely claim construction for “mechanically activated visual display”?

“Mechanically activated” requires a physical mechanical action to cause the display state to change. The claim is directed to a display coupled to the inhaler’s operating mechanism, rather than an electronic display controlled by a sensor or software.

Likely covered mechanisms include:

A sliding indicator moved by a metering button.
A rotating disk indexed by dose preparation.
A shutter moved by a lever.
A flag that appears or disappears after actuation.
A mechanical linkage between dose preparation and display movement.

Potentially distinguishable designs include:

Electronic displays driven by pressure, optical, or electronic sensors.
Smartphone-connected dose tracking without a mechanically changed physical display.
Displays that respond only to inhalation and have no metering-button linkage.
Counters that record dose use but do not indicate immediate readiness.

The claim does not require the display to be electronic, digital, numerical, or removable unless those limitations appear in a particular dependent claim.

What patent expiration date applies to U.S. Patent 6,071,498?

The patent issued June 6, 2000. Under the modern U.S. patent-term statute, utility patents generally expire 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and specific transitional rules. [2]

For U.S. Patent 6,071,498, the ordinary term expired in approximately 2017-2018. The patent is now expired and cannot block a current generic or device competitor from practicing the claimed subject matter.

The expiration analysis is commercially significant:

No current blocking patent rights arise from the issued claims.
No Orange Book patent listing is created by this device patent.
A competitor does not need a patent-term certification to practice the expired claims.
Any current risk would have to arise from later patents, continuation patents, design patents, trade secrets, regulatory exclusivity, or unrelated drug and formulation patents.

What is the Orange Book status of U.S. Patent 6,071,498?

U.S. Patent 6,071,498 is not an active Orange Book drug patent. The FDA Orange Book lists patents submitted by New Drug Application holders for approved drug products, including patents covering active ingredients, formulations, compositions, and approved methods of use. [3]

A standalone inhaler-device patent generally is not an Orange Book patent unless the device is submitted as a patentable aspect of an approved drug-device combination and satisfies FDA listing requirements.

The patent therefore does not provide:

Five-year new chemical entity exclusivity.
Three-year clinical-investigation exclusivity.
Pediatric exclusivity.
Orphan-drug exclusivity.
A current 30-month stay based on a Paragraph IV certification.

Paragraph IV litigation is relevant only when a generic applicant challenges an unexpired Orange Book-listed patent. This patent, as an expired inhaler-device patent, is not an apparent current Paragraph IV asset.

Does U.S. Patent 6,071,498 cover drug formulations or methods of use?

No. The claims are apparatus claims.

Formulation patents

The patent does not claim:

Particle-size distribution.
Micronized active ingredient.
Lactose carrier ratios.
Moisture-control agents.
Excipient selection.
Powder blend uniformity.
Aerodynamic particle-size characteristics.

A formulation could be used in an inhaler that falls within the expired claims, but the formulation itself is not protected by this patent.

Method-of-use patents

The patent does not claim administration of a particular drug for asthma, chronic obstructive pulmonary disease, or another condition. It does not require a dose amount, treatment duration, patient population, or therapeutic indication.

Method-of-use risk must be assessed against separate patents owned by the relevant drug manufacturer.

Manufacturing and process patents

The patent does not claim manufacture of the powder, filling of a cartridge, assembly of a dose counter, or calibration of a metering mechanism. Later manufacturing patents could still create risk if they claim a specific production process or device-assembly method.

How strong was the patent estate based on the claim structure?

The patent had moderate technical breadth but limited modern enforcement breadth.

Strengths

Claim 1 ties the readiness display to a two-step operating sequence.
Claim 9 creates a separate claim path based on dual visual displays.
The claims cover both inhaler-mounted and cartridge-associated dose displays.
Dependent claims address practical device placement and user visibility.
The claims are technology-neutral regarding the exact mechanical display structure.

Limitations

The claims require powdered medicament delivery.
Claim 1 requires a metering button and two-step operation.
Claim 1 expressly requires mechanical activation.
Claim 9 requires separate readiness and dose-use display functions.
Several dependent claims require a replaceable cartridge.
The claims do not cover electronic adherence systems in general.
The patent has expired.

The strongest historical design-around strategies would have included removing the separate preparation button, using an inhalation-triggered mechanism, placing the dose counter outside the cartridge, using electronic sensing, or eliminating a distinct readiness display.

Which competing patent categories matter for current inhaler freedom to operate?

The expired patent remains relevant as prior art and as a design-history reference, but current freedom-to-operate analysis should focus on later patent families in five categories.

Dose-metering mechanisms

These patents cover:

Reservoir-based dosing.
Blister-strip indexing.
Capsule piercing.
Unit-dose loading.
Lever or button actuation.
Inhalation-triggered release.

Dose counters and adherence systems

Later patents commonly claim:

Mechanical dose counters.
Electronic dose counters.
Optical dose detection.
Audible or tactile feedback.
Wireless transmission of dose events.
Patient-use data logging.

Cartridge and refill systems

Relevant claims may cover:

Replaceable powder cartridges.
Cartridge authentication.
Cartridge dose tracking.
Cartridge sealing.
Moisture barriers.
Refill lockout mechanisms.

Formulation and powder engineering

Drug companies frequently protect:

Specific active ingredients.
Salt or polymorph forms.
Carrier-based dry-powder blends.
Particle engineering.
Stabilized formulations.
High-dose powder compositions.

Combination-product integration

A commercial inhaler may be subject to separate rights covering:

The drug-device combination.
The delivery profile.
Dose uniformity.
Device-specific labeling.
Digital monitoring.
Connected-device software.

What litigation, settlements, or licensing deals affect this patent?

The supplied claims establish the patent’s technical scope but do not establish a current litigation, settlement, or licensing position. Because the patent is expired, any historical litigation would have no current exclusivity effect unless it produced a separate contractual restriction or a surviving patent family.

The patent should therefore be treated as:

A historical device patent.
A potential prior-art reference.
A source of expired claim scope.
Not a current litigation blocker.

No current FDA exclusivity, Orange Book listing, biosimilar barrier, or generic launch restriction follows from U.S. Patent 6,071,498 alone.

How does this patent compare with drug, formulation, and biologic patents?

Patent category	Typical protected subject matter	Relevance of U.S. 6,071,498
Active-ingredient patent	Chemical compound or biologic molecule	None
Formulation patent	Powder blend, excipient, particle properties	None
Method-of-use patent	Treatment indication or dosing regimen	None
Inhaler-device patent	Metering, actuation, displays, cartridge structure	Direct
Manufacturing patent	Filling, assembly, powder processing	Limited
Orange Book patent	Drug-product patent tied to an NDA	Not ordinarily
Biosimilar patent	Biologic composition, process, formulation, use	None

Biosimilar risk is not applicable because the patent does not claim a biologic product or biologic manufacturing process. Generic risk, if any, would arise from separate drug and device patents, not from this expired patent.

What generic launch scenarios exist after expiration?

A generic or authorized-generic developer can generally practice the expired claims without waiting for patent expiration. Commercial launch risk would instead depend on:

Active-ingredient patent status.
Formulation and composition patents.
Approved method-of-use patents.
Device patents issued after the relevant filing date.
Regulatory requirements for the inhaler-drug combination.
Substitutability and product-specific FDA approval requirements.
Manufacturing know-how and cartridge supply.

Three practical launch scenarios follow:

Scenario	Patent impact of U.S. 6,071,498	Primary remaining risk
Same mechanical display architecture	No current blocking effect	Later device or drug patents
Simplified inhaler without readiness display	No infringement concern from this patent	Regulatory equivalence and performance
Electronic or sensor-based counter	Outside several historical limitations	Later digital-device patents

Key Takeaways

U.S. Patent 6,071,498 covers dry-powder inhaler architecture, not a drug or formulation.
Claim 1 focuses on a metering-button preparation step followed by inhalation and a mechanically activated readiness display.
Claim 9 separately covers first and second visual displays for readiness and dose removal.
Claims 2, 4, and 11 address replaceable cartridges and cartridge-based dose displays.
Claims 5 through 8 and 13 through 14 protect display visibility from the mouthpiece side or in the normal inhalation position.
The patent does not claim formulation composition, treatment methods, active ingredients, or biologics.
The patent’s ordinary term expired in approximately 2017-2018.
It is not a current Orange Book or Paragraph IV barrier.
Current freedom-to-operate risk must be assessed against later inhaler, cartridge, formulation, manufacturing, and drug-product patents.
Biosimilar risk is not implicated by this patent.

FAQs

Can a company copy the dose-readiness display described in U.S. Patent 6,071,498?

Yes, the patent is expired. A company may practice the expired claims, subject to any later patent covering the same mechanism or a related drug-device combination.

Does the patent cover a metered-dose inhaler using a propellant?

Not on the claim language provided. The claims are directed to powdered medicaments delivered through an air stream. A propellant-based metered-dose inhaler would not automatically satisfy the powdered-medicament limitation.

Does a digital inhaler dose counter infringe claim 1?

Not necessarily. Claim 1 expressly requires a mechanically activated visual display. A purely electronic counter may avoid literal infringement, although the full device and any later patents must be analyzed separately.

Can this patent be used to block a generic dry-powder inhaler in the United States?

No. Its patent term has expired. A generic applicant would evaluate current drug, formulation, method-of-use, and later device patents instead.

Is a replaceable cartridge required for all claims?

No. Claims 1 and 9 do not require a replaceable cartridge. Cartridge limitations appear in dependent claims 2, 4, and 11, together with related display and viewing limitations.

References

United States Patent No. 6,071,498, Inhaler for powdered medicaments (June 6, 2000).
United States Patent and Trademark Office. (2023). Manual of Patent Examining Procedure § 2710: Patent term.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	195 22 416	Jun 21, 1995
Germany	195 22 415	Jun 21, 1995

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	002534	⤷ Start Trial
Austria	209518	⤷ Start Trial
Australia	6221196	⤷ Start Trial
Australia	719449	⤷ Start Trial
Brazil	9608997	⤷ Start Trial
Canada	2225396	⤷ Start Trial
Canada	2378713	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 6,071,498